Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 5/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2GAATERTCDK8MAPK8 | |
| SCHEMBL15825839 | 0.85 | GAA (0.43) | SMN1; SMN2GAATERTKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL7813040 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2GAATERTCDK8MAPK8 | |
| SCHEMBL8055642 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2GAATERTCDK8MAPK8 | |
| SCHEMBL10918267 | 0.81 | GAA (0.40) | SMN1; SMN2GAAKDM4ELMNANPC1 | |
| SCHEMBL28038425 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2GAATERTCDK8CDK19 | |
| SCHEMBL7008426 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2TERTCDK8MAPK8DAPK3 | |
| SCHEMBL27488817 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2GAATERTKDM4ELMNA | |
| SCHEMBL6717347 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2TERTCDK8MAPK8DAPK3 | |
| SCHEMBL13742735 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2TERTCDK8MAPK8DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638227-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229079-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | WO | disclosed |
| CN-105037346-A | Pyrazol bi-amide compounds containing 1,2,3-thiadiazole and synthetic method and application thereof | UNIV CHINA AGRICULTURAL | 2015-11-11 | — | — | CN | disclosed |
| CN-102267986-B | Pyrazole bisamide compounds as well as synthesis method and application thereof | UNIV CHINA AGRICULTURAL | 2014-04-16 | — | — | CN | disclosed |
| CN-1229349-C | Pyridine-3-carboxylic acid derivative | PFIZER (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1495169-A | Pyridine-3-carboxylic acid derivative | — | 2004-05-12 | — | — | CN | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1854/4885GAA 3394/4885TERT 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.